TGIF2LX1 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the TGIF2LX1 protein, which is a member of the TGIF (thymine-rich, G-rich, and immunoglobulin-like factors) family. This protein plays a significant role in regulating gene expression and cellular development, particularly in the context of embryonic development and patterning. TGIF2LX1 acts as a transcriptional co-repressor, modulating the activity of various transcription factors by binding to their target genes. Inhibition of TGIF2LX1 is achieved primarily by binding to its critical regions, such as the DNA-binding domain or interaction sites essential for recruiting other proteins involved in transcriptional regulation. By occupying these binding sites, TGIF2LX1 inhibitors effectively disrupt the protein's normal regulatory functions, leading to altered gene expression profiles. Some inhibitors may also function through allosteric mechanisms, binding to regions separate from the active site and inducing conformational changes that diminish the protein's activity. The binding interactions between these inhibitors and TGIF2LX1 are typically stabilized by a range of non-covalent forces, including hydrogen bonds, hydrophobic interactions, van der Waals forces, and ionic interactions.
Structurally, TGIF2LX1 inhibitors demonstrate considerable diversity, enabling specific interactions with different regions of the TGIF2LX1 protein. These inhibitors often incorporate functional groups such as hydroxyl, carboxyl, or amine groups, facilitating strong interactions through hydrogen bonding and ionic interactions with key amino acid residues in the protein's binding pockets. Many TGIF2LX1 inhibitors also feature aromatic rings or heterocyclic structures that enhance hydrophobic interactions with non-polar regions of the protein, thereby contributing to the overall stability of the inhibitor-protein complex. The physicochemical properties of TGIF2LX1 inhibitors, including molecular weight, solubility, lipophilicity, and polarity, are meticulously optimized to ensure effective binding and stability in various biological environments. This balance between hydrophilic and hydrophobic regions allows TGIF2LX1 inhibitors to interact selectively with both polar and non-polar areas of the protein, ensuring robust and efficient inhibition of TGIF2LX1 activity across diverse cellular contexts.
| 製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
|---|---|---|---|---|---|---|
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
TGF-β受容体キナーゼ阻害剤として、LY364947はそのシグナル伝達カスケードの活性化を阻害することにより、TGIF2LXの発現を低下させる可能性がある。 | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
このTGF-β受容体Iの選択的阻害剤は、TGF-βを介した転写活性化を阻害することにより、TGIF2LXの発現を抑制する可能性がある。 | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
RepSoxはTGF-β受容体の選択的阻害剤であり、TGF-βシグナル伝達を減弱させることでTGIF2LXの発現を減少させることができる。 | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $100.00 $408.00 | 6 | |
この低分子は、TGF-βを介する線維化反応を調節することによって、間接的にTGIF2LXの発現を低下させる可能性がある。 | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1740.00 | ||
HalofuginoneはTGF-βシグナルを阻害し、おそらくその下流の遺伝子制御を阻害することによってTGIF2LXの発現を低下させる。 | ||||||
Tranilast | 53902-12-8 | sc-200389 sc-200389A sc-200389B sc-200389C | 10 mg 50 mg 1 g 5 g | $30.00 $101.00 $277.00 $959.00 | 2 | |
トラニラストは、TGF-βに拮抗し、その関連転写活性を低下させることにより、TGIF2LXの発現を阻害する可能性がある。 | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $86.00 | 3 | |
TGF-β受容体Iキナーゼ阻害剤として、SD-208はTGF-βシグナル伝達経路を遮断することにより、TGIF2LXの発現を低下させることができた。 | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
EW-7197はTGF-βシグナルを阻害し、その誘導機構を阻害することによってTGIF2LXの発現低下につながる可能性がある。 | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $87.00 $270.00 | 9 | |
TGF-β受容体Iのキナーゼ活性を阻害することにより、TGIF2LXの発現を低下させ、そのシグナル伝達経路を遮断する。 | ||||||
Ceralasertib | 1352226-88-0 | sc-507439 | 10 mg | $573.00 | ||
Vactosertibは、TGF-β受容体Iを阻害することで、そのシグナル伝達経路を抑制し、TGIF2LXの発現を低下させる可能性がある。 | ||||||